Држава: Канада
Језик: Енглески
Извор: Health Canada
IBUPROFEN
APOTEX INC
M01AE01
IBUPROFEN
400MG
TABLET
IBUPROFEN 400MG
ORAL
100
OTC
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0108883002; AHFS:
APPROVED
2019-07-05
Page 1 of 41 0 PRODUCT MONOGRAPH APO -IBUPROFEN IBUPROFEN TABLETS USP, 200 MG APO -IBUPROFEN CAPLET IBUPROFEN TABLETS USP, 200 MG APO -IBUPROFEN IBUPROFEN TABLETS USP, 300 MG APO -IBUPROFEN IBUPROFEN TABLETS USP, 400 MG APO -IBUPROFEN CAPLET IBUPROFEN TABLETS USP, 400 MG NON-STEROIDAL ANTI-INFLAMMATORY DRUG ANALGESIC, ANTIPYRETIC AGENT APOTEX INC. 150 SIGNET DRIVE TORONTO, ONTARIO DATE OF REVISION: M9L 1T9 OCTOBER 19, 2020 Submission Control No: 240021 Page 2 of 41 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................... 3 SUMMARY PRODUCT INFORMATION ...................................................................................... 3 INDICATIONS AND CLINICAL USE............................................................................................ 4 CONTRAINDICATIONS ................................................................................................................. 4 WARNINGS AND PRECAUTIONS ............................................................................................... 5 ADVERSE REACTIONS ............................................................................................................... 11 DRUG INTERACTIONS ................................................................................................................ 14 DOSAGE AND ADMINISTRATION ............................................................................................ 16 OVERDOSAGE .............................................................................................................................. 17 ACTION AND CLINICAL PHARMACOLOGY .......................................................................... 18 STORAGE AND STABILITY ....................................................................................................... 19 SPECIAL HANDLING INSTRUCTIONS……………………………………………………......19 DOSAGE FORMS, COMPOSITION AND PACKAGING ..................................................... Прочитајте комплетан документ